Merck

(IN BRIEF) Merck is investing €62 million in a new quality control facility at its Darmstadt headquarters as part of a larger €1.5 billion investment program. Scheduled for completion by mid-2025, the state-of-the-art facility will consolidate 135 employees into a … Read the full press release →

(IN BRIEF) Merck, a leading science and technology company, has inaugurated its expanded Life Science distribution center in Schnelldorf, Germany, following a €180 million investment that nearly doubled its size to 25,000 square meters. The upgraded facility now includes manual … Read the full press release →

(IN BRIEF) AstraZeneca is set to revolutionize cancer care with a slew of groundbreaking data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting. Over 100 abstracts will showcase 25 approved and potential new medicines, including two late-breaking … Read the full press release →

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated significant progress in treating HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy. The high-level results from the DESTINY-Breast06 Phase … Read the full press release →

(IN BRIEF) AstraZeneca’s Truqap, in combination with Faslodex, has received a positive recommendation from the European Medicines Agency (EMA) for treating estrogen receptor-positive, HER2‑negative locally advanced or metastatic breast cancer with specific genetic alterations. The recommendation follows promising results from … Read the full press release →

(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acknowledged by the US FDA for treating adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received prior systemic … Read the full press release →

(IN BRIEF) AstraZeneca announces the approval of Truqap (capivasertib) in combination with Faslodex (fulvestrant) by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating adult patients with unresectable or recurrent hormone receptor-positive, HER2-negative breast cancer. The approval, based … Read the full press release →

(IN BRIEF) Merck, a prominent science and technology company, announces a €14 million expansion of its M LabTM Collaboration Center in Shanghai, bolstering its support for the biopharmaceutical industry in China. The expansion includes new facilities such as a biology … Read the full press release →

(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release →

(IN BRIEF) E. Merck KG, representing the Merck family’s interests in Merck KGaA, has disclosed the results of its regular board elections. Johannes Baillou, with 30 years of board experience at E. Merck KG, has been elected as Chairman of … Read the full press release →

(IN BRIEF) Merck, a leading science and technology company, has inaugurated the Merck Digital Hub in Singapore, its first digital hub outside of the US and Europe. Supported by the Singapore Economic Development Board (EDB), the hub aims to accelerate … Read the full press release →

(IN BRIEF) EQT has unveiled its EQT Healthcare Growth Strategy and revealed its initial investment in Mabtech, acquired from the IK Small Cap II Fund. The strategy aims to capitalize on long-term healthcare trends, leveraging scientific breakthroughs, technology advancements, and … Read the full press release →

(IN BRIEF) The global life sciences industry has witnessed a resurgence in mergers and acquisitions (M&A) activity, with investments totaling $191 billion by December 10, 2023, compared to $142 billion in 2022. Although the number of completed deals decreased, the … Read the full press release →

(IN BRIEF) Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds, currently under Phase II evaluation for the second-line … Read the full press release →

(IN BRIEF) Merck has completed the second phase of its new €29 million Biologics Testing Center in China, adding 1,500 square meters to the facility. This expansion includes the first biosafety laboratories for Merck in the Chinese market, enabling clients … Read the full press release →

(IN BRIEF) AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has gained approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer possessing specific … Read the full press release →

(IN BRIEF) AstraZeneca has reported positive high-level results from the EMERALD-1 Phase III trial, demonstrating that its drug Imfinzi (durvalumab), in combination with transarterial chemoembolisation (TACE) and bevacizumab, significantly improves progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC) eligible … Read the full press release →

(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This collaboration includes an exclusive global license (excluding China) to develop and commercialize Hengrui’s advanced PARP1 inhibitor, HRS-1167. Additionally, there is … Read the full press release →

(IN BRIEF) Merck, a leading science and technology company, has announced its expectation to return to organic sales growth in fiscal 2024. This was revealed during the company’s Capital Markets Day. Despite challenging market conditions in its Life Science and … Read the full press release →

(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. These abstracts will showcase the latest research on Merck’s oncology portfolio, addressing … Read the full press release →